___

Allen TM., Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews 2013; 65: 36-48.

Bento D., Staats HF., Gonçalves T., Borges O. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. European Journal of Pharmaceutics and Biopharmaceutics 2015; 93: 149-164.

Bozzuto G., Molinari A. Liposomes as nanomedical devices. International Journal of Nanomedicine 2015; 10: 975-999.

Brownlie R., Allan B. Avian toll-like receptors. Cell and Tissue Research 2011; 343: 121-130.

Brunner R., Jensen-Jarolim E., Pali-Schöll I. The ABC of clinical and experimental adjuvants-a brief overview. Immunology Letters 2010; 128: 29-35.

Coffman RL., Sher A., Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33: 492-503.

Cokcaliskan C., Turkoglu T., Sareyyupoglu B., Uzunlu E., Babak A., Özbilge BB., Gülyaz V. QS-21 enhances the early antibody response to oil adjuvant foot and-mouth disease vaccine in cattle. Clinical and Experimental Vaccine Research 2016; 5(2):138-147.

Cordeiro AS., Alonso MJ., de la Fuente M. Nanoengineering of vaccines using natural polysaccharides. Biotechnology Advances 2015; 33: 1279-1293.

Cunha IALD., Zulpo DL., Bogado ALG., Barros LDD.,Taroda A., Igarashi M., Navarro IT. Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A. Veterinary Parasitology 2012; 186(3-4): 216-221.

Dandashli EA., Zhao Q., Yitta S., Morefield GL., White JL. Hem SL. Effect of thermal treatment during the preparation of aluminum hydroxide adjuvant on the protein adsorption capacity during aging. Pharmacuetical Development and Technology 2002; 7(4): 401-406.

Dar A., Lai K., Dent D., Potter A., Gerdts V., Babiuk LA., Mutwiri GK. Administration of poly (di(sodium carboxylatoethylphenoxy))phosphazene (PCEP) as adjuvant activated mixed Th1/Th2 immune responses in pigs. Veterinary Immunology and Immunopathology 2012; 146(3-4): 289-295.

Dell’Era L., Corona F., Daleno C., Scala A., Principi N., Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 2012; 30: 936-940.

Dowling JK, Dellacasagrande J. Toll-like receptors: ligands, cell-based models and readouts for receptor action. Methods in Molecular Biology 2016; 1390: 3-27.

Freund J., Casals J., Hosmer EP. Sensitization and antibody formation after injection of tubercle Bacilli and paraffin oil. Experimental Biology and Medecine 1937; 37: 509-513.

Garg R., Latimer L., Gerdts V., Potter A., van Drunen Littel-van den Hurk S. The respiratory syncytial virus fusion proteinformulated with a novel combination adjuvant inducesbalanced immune responses in lambs with maternal antibodies.Vaccine 2015; 33: 1338-1344.

Garlapati S., Garg R., Brownlie R., Latimer L., Simko E., Hancock REW., Babiuk LA., Gerdths V., Potter A., van Drunen S., Hurk van Den. Enhanced immune responses and protectionby vaccination with respiratory syncytial virus fusionprotein formulated with CpG oligodeoxynucleotide and innatedefense regulator peptide in polyphosphazene microparticles.Vaccine 2012; 30(35): 5206-5214.

Geijtenbeek TBH., Gringhuis SI. C-type lectin receptors in the control of T helper cell differentiation. Nature Reviews Immunology 2016; 16: 433-448.

Gerdts V. Adjuvants for veterinary vaccines-types and modes of action. Berliner und Münchener tierärztliche Wochenschrift 128(11): 456-463.

Glenny AT., Pope CG., Waddington H.,Wallace U. Immunological notes. XVI1-XXIV.The Journal of Pathology and Bacteriology 1926; 29: 31-40.

Gracia A., Polewicz M., Halperin SA., Hancock REW., Potter AA., Babiuk LA., Gerdts V. Antibody responses in adult andneonatal BALB/c mice to immunization with novel Bordetellapertussis vaccine formulations. Vaccine 2011; 29(8): 1595-1604.

Gregoriadis G. Liposome research in drug delivery: The early days. Journal of Drug Targeting 2008; 16: 520-524.

Gupta RK. Aluminum compounds as vaccine adjuvants. Advanced Drug Delivery Reviews 1998; 32: 155- 172.

He Q., Mitchell AR., Johnson SL., Wagner-Bartek C., Morcol T. Calcium phosphate nanoparticle adjuvant. Clinical and Diagnostic Laboratory Immunology 2000; 7(6): 899-903.

Hiszczynska-Sawicka E., Li H., Xu JB., Akhtar M., Holec-Gasior L., Kur J., Bickerstaffe R. Induction of immune responses in sheep by vaccination with liposome-entrapped DNA complexes encoding Toxoplasma gondii MIC3 gene. Polish Journal of Veterinary Sciences 2012; 15(1): 3-9.

HogenEsch H. Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine 2002; 20(Suppl 3): S34-S39.

Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004; 5: 987-995.

Jaganathan KS., Singh P., Prabakaran D., Mishra V., Vyas SP.Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis. Journal of Pharmacy and Pharmacology 2004; 56: 1243-1250.

Jorge S., de Oliveira NR., Marchioro SB., Fisch A., Gomes CK., Hartleben CP., Conceiçao FR., Dellagostin OA. The mycoplasma hyopneumoniae recombinant heat shock protein P42 induces an immune response in pigs under field conditions. Comparative Immunology, Microbiology & Infectious Diseases 2014; 37: 229-236.

Joyappa DH., Kumar CA., Banumathi N., Reddy GR., Suryanarayana VV. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virüs. Veterinay Microbiology 2009; 139: 58-66.

Jungi TW., Farhat K., Burgener IA.,Werling D. Tolllike receptors in domestic animals. Cell and Tissue Research 2011; 343: 107-120.

Kensil CR. Saponins as vaccine adjuvants. Critical Reviews in Therapeutic Drug Carrier Systems 1996; 13: 1-55.

Khong H., Overwijk WW. Adjuvants for peptide-based cancer vaccines. Journal for ImmunoTherapy of Cancer Immunother Cancer 2016; 4: 56.

Khorasani A., Madadgar O., Soleimanjahi H., Keyvanfer H., Mahravani H. Evaluation of the efficacy of a new oil-based adjuvant ISA 61 VG FMD vaccine as a potential vaccine for cattle. Iranian Journal of Veterinary Research 2016;17: 8-12.

Kool M., Fierens K., Lambrecht BN. Alum adjuvant: Some of the tricks of the oldest adjuvant. Journal of MedicalMicrobiology2012; 61(Pt 7): 927-934.

Korsholm KS., Andersen PL., Christensen D. Cationic liposomal vaccine adjuvants in animal challenge models: Overview and current clinical status. Expert Review of Vaccines 2012; 11: 561-577.

Kwong LS., Parsons R., Patterson R., Coffey TJ., Thonur L., Chang TS., Russell G., Haig D., Werling D., Hope JC. Characterisation of antibodies to bovine toll-like receptor (TLR)-2 and cross-reactivity with ovine TLR2. Veterinary Immunology andImmunopathology 2011; 139: 313-318.

Lee S., Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Network 2015; 15: 51-57.

Leleux J., Roy K. Micro and nanoparticle based delivery system for vaccine immunotherapy: an immunological and material perspective. Advance Healthcare Materials 2013; 2: 72-94.

Li W., Watarai S., Iwasaki T., Kodama H. Suppression of Salmonella enterica serovar Enteritidis excretion by intraocular vaccination with fimbriae proteins incorporated in liposomes. Developmental and Comparative Immunology 2004; 28(1): 29-38.

Mair KH., Koinig H., Gerner W., Hohne A., Bretthauer J., Kroll JJ., Roof MB., Saalmüller A., Stadler K., Libanova R. Carbopol improves the early cellular immune responses induced by the modified-life vaccine Ingelvac PRRS MLV. Veterinary Microbiology 2015; 176(3-4): 352-357.

Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discovery Today 2003; 8: 934-943.

Moyer TJ., Zmolek AC., Irvine DJ. Beyond antigens and adjuvants: Formulating future vaccines. The Journal of Clinical İnvestigation 2016; 126: 799-808.

Muzzarelli R. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Marine Drugs 2010; 8: 292-312.

Olmedo H., Herrera M., Rojas L., Villalta M., Vargas M., Leiguez E., Teixeria C., Estrada R., Gutierrez JM., Leon G., Montero ML. Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom. Journal of Immunotoxicology 2014; 11(1): 44-49.

Onuigbo EB., Okore VC., Ofokansi KC., Okoye JOA., Nworu CS., Esimone CO., Attama AA. Preliminary evaluation of the immunoenhancement potential of Newcastle disease vaccine formulated as a cationic liposome. Avian Pathology 2012; 41(4): 355-360.

Paillot R. A systematic review of recent advances in equine influenza vaccination. Vaccines 2014; 2: 797- 831.

Pan L., Zhang Z., Lv J., Zhou P., Hu W., Fang Y., Chen H., Liu X., Shao J., Zhao F., Ding Y., Lin T., Chang H., Zhang J., Zhang Y., Wang Y. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles. International Journal of Nanomedicine 2014; 9: 5603-5618.

Perrie Y., Crofts F., Devitt A., Griffiths HR., Kastner E., Nadella V. Designing liposomaladjuvants for the next generation of vaccines. Advanced Drug Delivery Reviews 2016; 99: 85-96.

Petrovsky N. Comparative safety of vaccine Adjuvants: a summary of current evidence and future needs. Drug Safety 2015; 38: 1059-1074.

Pini A., Danskin D., Coackley W. Comparative evaluation of the potency of beta-propiolactone inactivated Newcastle disease vaccines prepared from a lentogenic strain and a velogenic strain. Veterinary Record 1965; 77: 127.

Rauw F., Gardin Y., Palya V., Anbari S., Gonze M., Lemaire S., van den Berg T., Lambrecht B. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Veterinary Immunology and Immunopathology 2010; 134(3-4): 249- 258.

Ren J., Yang L., Xu H., Zhang Y., Wan M., Liu G., Zhao L., Wang L., Yu Y. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle. Vaccine 2011; 29(45): 7960-7965.

Sahdev P., Ochyl LJ., Moon JJ. Biomaterials for nanopaticle vaccine delivery system. Pharmaceutical Research 2014; 31: 2563-2582.

Santos FN., Borja-Cabrera GP.,Miyashiro LM.,Grechi J., Reis AB., Moreira MAB., Filho OAM., Luvizotto MCR., Menz I., Pessoa LM., Gonçalves PR., Palatnik M., Palatnik-de Souza CB. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 2007; 25(33): 6176-6190.

Sellers RF., Herniman KAJ. Early protection of pigs against foot and mouth disease. British Veterinary Journal 1974; 130: 440-445.

Sesardic D., Rijpkema S., Patel BP. New adjuvants: EU regulatory developments. Expert Review of Vaccines 2007; 6: 849-861.

Silveira F., Cibulski SP., Varela AP., Marques JM., Chabalgoity A., de Costa F., Yendo ACA., Gosmann G., Roehe PM., Fernandez C., Ferreira F. Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation. Vaccine 2011; 29(49): 9177-9182.

Sparg SG., Light ME., van Staden J. Biological activities and distribution of plant saponins. Journal of Ethnopharmacology 2004; 94(2-3): 219-243.

Sun HX., Xie Y., Ye YP. Advances in saponin-based adjuvants. Vaccine 2009; 27: 1787-1796.

Suzuki N., Hazama S., Iguchi H., Uesugi K., Tanaka H. et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Science 2017; 108(1): 73-80.

Takeda K., Hemmi H., Akira S. Mechanism for recognition of CpG DNA. In: Hackett CJ, and Harn DA, eds. Vaccine Adjuvants: Immunological and Clinical Principles. Totowa, NJ: Humana Press, 2006: 69-86.

Uenishi H., Shinkai H. Porcine Toll-like receptors: The front line of Pathogen monitoring and possible implications for disease resistance. Developmental and Comparative Immunology 2009; 33: 353-361.

Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson LA. The common vaccine adjuvant aluminum hydroxide upregulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infection and Immunology 2001; 69: 1151-1159.

Vecchi S., Bufali S., Skibinski DA., O’Hagan DT., Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. Journal of Pharmaceutical Sciences 2012; 101: 17-20.

Weissig V. Liposomes came first:The early history of liposomology. Methods in Molecular Biology 2017; 1522: 1-15.

Xia Y., Fan Q., Hao D., Wu J., Ma G., Su Z. Chitosan-based mucosal adjuvants: Sunrise on the ocean. Vaccine 2015; 33(44): 5997-6010.

Yaguchi K., Ohgitani T., Noro T., Kaneshige T., Shimizu Y. Vaccination of chickens with liposomal inactivated avian pathogenic Escherichia coli (APEC) vaccine by eye drop or coarse spray administration. Avian Diseases Digest 2009; 53(2): 245-249.

Yau KP., Schulze DG., Johnston CT., Hem SL. Aluminum hydroxide adjuvant produced under constant reactant concentration. Journal of Pharmaceutical Sciences 2006; 95: 1822-1833.

Zhu D., Tuo W. QS-21: A potent vaccine adjuvant. Natural Products Chemistry and Research 2015; 3:e113.

Zulpo DL., Headley SA., Biazzono L., da Cunha IA., Igarashi M., Danielde LB., Taroda A., Cardim TC., Bogado ALG., Navarro IT., Garcia JL. Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii. Experimental Parasitology 2012; 131(2): 223-230.